logo-loader
viewRedx Pharma Plc

Details from Redx ROCK2 inhibitor poster

/**/ p{margin-right:0cm;margin-bottom:5.25pt;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 }visited{ color: #954F72 } .an{size:595.3pt 841.9pt;margin:2.0cm 2.0cm 2.0cm 2.0cm;}div.an{}p.bb{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center}p.bc{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal}p.bd{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal}p.be{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify}table.bf{width:451.3pt;margin-left:.75pt}td.au{width:344.15pt;padding:0cm 0cm 0cm 0cm}p.bg{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm}td.at{width:107.15pt;padding:0cm 0cm 0cm 0cm} tr.aq{height:4.0pt}td.as{width:344.15pt;padding:0cm 0cm 0cm 0cm; height:4.0pt}td.ar{width:107.15pt;padding:0cm 0cm 0cm 0cm; height:4.0pt}p.bh{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: right} /**/
RNS Number : 2407F
Redx Pharma plc
26 October 2018
 

REDX PHARMA PLC

("Redx" or "the Company")

 

Redx announces details from the ROCK2 inhibitor poster presented at the ASN Kidney Week 2018 in San Diego

 

Alderley Park, 26 October 2018 Redx (AIM: REDX), the drug development company focused on cancer and fibrosis, is pleased to announce that the Company has presented a poster, entitled 'ROCK2 inhibitors for the treatment of chronic kidney disease' at the American Society of Nephrology (ASN) Kidney Week 2018 in San Diego, CA, on 25 October 2018.

 

This first disclosure of the Redx ROCK2 selective inhibitor programme describes a series of potent and highly selective ROCK2 inhibitors that potently suppress the release of pro-fibrotic factors from kidney mesangial cells. In an in vivo model of acute kidney injury, the Redx selective ROCK2 tool compound reduced podocyte damage and the expression of inflammatory and profibrotic genes in the kidney. In addition, a telemetered rat study indicated that the Redx selective ROCK2 inhibitor avoids the cardiovascular side-effects typically observed with systemic pan-ROCK inhibitors.

 

Redx believe that their highly selective ROCK2 inhibitors could provide a novel and effective therapy for patients with progressive kidney fibrosis associated with diabetes, who currently have few, largely ineffective, therapeutic options.

 

Richard Armer, Chief Scientific Officer commented: "We are pleased that our poster was presented at the high profile American Society of Nephrology Kidney Week. We believe our highly selective ROCK2 inhibitors have the potential to be best-in-class agents for the treatment of fibrotic diseases of the kidney such as diabetic nephropathy (DN) and of the liver such as non-alcoholic steatohepatitis (NASH). This is the first publication of our ROCK2 project data and we are delighted that the high quality of our research has been recognised by the ASN." 

 

The poster, entitled 'ROCK2 inhibitors for the treatment of chronic kidney disease' presented at the American Society of Nephrology (ASN) Kidney Week 2018 in San Diego, CA, on 25 October 2018, can be accessed here: ROCK2 inhibitors for the treatment of chronic kidney disease

 

For further information, please contact:

Redx Pharma Plc

T: +44 1625 469 920

Lisa Anson, Chief Executive Officer

Andrew Saunders, Chief Medical Officer

Richard Armer, Chief Scientific Officer

 

 

 

Cantor Fitzgerald Europe (Nominated Advisor & Broker)

 T: +44 20 7894 7000

Phil Davies

 

 

 

WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson

 

 

 

FTI Consulting

T: +44 20 3727 1000

Simon Conway/Stephanie Cuthbert

 

 

About Redx Pharma Plc 

Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.

 

If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
UPDBUBDGXUDBGIU

Quick facts: Redx Pharma Plc

Price: 7.05

Market: AIM
Market Cap: £8.92 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Redx Pharma gets green light to increase dose in lead cancer...

Redx Pharma PLC (LON:REDX) CEO Lisa Anson spoke to Proactive London's Andrew Scott following the news they've been given the go-ahead to up the dose of its lead cancer drug. It comes after the firm successfully navigated the first part of its early-stage trial for RXC004. The asset's part...

on 20/8/19